TMET-65. SETD2 Loss Predicts Favorable Prognosis in Glioblastoma via Suppression of the Serine Synthesis Pathway
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1756
Abstract: Glioblastoma (GBM) is an aggressive primary brain tumor characterized by poor prognosis and limited treatment options. SETD2, a histone H3K36 trimethyltransferase, maintains genomic integrity and regulates transcriptional and metabolic processes. Although SETD2 loss has been… read more here.
Keywords: synthesis pathway; loss; prognosis; serine synthesis ... See more keywords
SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis
Sign Up to like & getrecommendations! Published in 2023 at "JCI Insight"
DOI: 10.1172/jci.insight.154120
Abstract: SETD2, a H3K36 trimethyltransferase, is the most frequently mutated epigenetic modifier in lung adenocarcinoma, with a mutation frequency of approximately 9%. However, how SETD2 loss of function promotes tumorigenesis remains unclear. Using conditional Setd2-KO mice,… read more here.
Keywords: tumorigenesis; setd2 loss; lung; setd2 ... See more keywords